Document is current
Any future updates will be listed below
-
Authors
Smith, Alexander L. W. https://orcid.org/0000-0003-1052-0096
Harmer, Catherine J. https://orcid.org/0000-0002-1609-8335
Cowen, Philip J. https://orcid.org/0000-0001-5518-6138
Murphy, Susannah E. https://orcid.org/0000-0001-8995-2099
-
Funding
Funding for this research was provided by:
Wellcome Trust (102176/B/13/Z)
NIHR Oxford Biomedical Research Centre
John Fell Fund, University of Oxford
- License Information
-
More Information
Article History
Accepted: 15 May 2023
First Online: 29 June 2023
Declarations
:
: AS is funded by a Wellcome Trust Clinical Doctoral Fellowship, grant reference 102176/B/13/Z. This research was supported the NIHR Oxford Health Biomedical Research Centre and an Oxford University John Fell Fund grant. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
: CJH has received consultancy fees from P1vital Ltd., Janssen Pharmaceuticals, Sage Therapeutics, Pfizer, Zogenix, Compass Pathways and Lundbeck. SEM has received consultancy fees from Zogenix, Sumitomo Dainippon Pharma, P1vital Ltd. and Janssen Pharmaceuticals. CJH and SEM hold grant income from Zogenix, UCB Pharma, Syndesi and Janssen Pharmaceuticals. CJH and PJC hold grant income from a collaborative research project with Pfizer and the MRC. The authors are currently conducting an experimental medicine study using NLX-101, which has been gifted by Neurolixis.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: ALWS, CJH, PJC and SEM were all involved in drafting and revising the manuscript. All authors have read and approved the final article.
